Developer docs
API playgroundTry for free, no card

Search company profiles

IBT Bioservices

Full company profile

uuid000sfej

Namestring
IBT Bioservices
Legal namestring
Integrated Biotherapeutics, Inc.
Company typeenum
Private
Founded yearint
2010
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, preclinical CRO services, infectious disease research, vaccine development services, biological reagent supply
Industry4 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Preclinical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1CRO Services Revenue
TypeProfessional Services
Description

Preclinical and clinical research services including in vitro assays, animal studies, GxP testing, custom assay development, and concierge services. Revenue generated through project-based contracts and service agreements with biotech, pharma, and government clients.

ibtbioservices.com
2Reagent Product Sales
TypeOne Time License
Description

Sale of research reagents including recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through e-commerce storefront and distribution partners.

ibtbioservices.com
3Grant Support Services
TypeProfessional Services
Description

Technical consulting and support services for SBIR, NIH, NIAID, BARDA, and DOD grant applications. The team has supported clients in securing over $150M in cumulative grant funding.

ibtbioservices.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
Pricing details1 tier
1Individual reagent products priced per unit
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Product prices range from approximately $300-$700 per unit for recombinant proteins and antibodies. Examples: Recombinant Zaire Ebola virus GPΔTM (Sf9) $634.00, Sudan virus sGP ELISA Kit $723.00, Mouse anti-Ebola Virus VP40 mAb $621.00

ibtbioservices.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

IBT Bioservices is a full-service clinical and preclinical Contract Research Organization (CRO) providing research services and biological reagents for vaccine and therapeutic development. The company delivers in vitro assays, animal models, GxP-compliant testing, and concierge program management targeting infectious disease pathogens including filoviruses, flaviviruses, and Staphylococcus aureus. It also manufactures and sells recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through its e-commerce storefront and distribution partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 120+ clients supported for grant applications with $150M+ cumulative funding secured
+2 more records
Product overview1 text field

IBT Bioservices is a Full Service Clinical & Preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of biological reagents and research services for vaccine and therapeutic development. The company's product portfolio includes Recombinant Proteins, Primary Antibodies, Pseudovirus, Virus Like Particles, ELISA Kits, Vaccine Adjuvants, and Cell Lines targeting viral pathogens (filoviruses including Ebola, Marburg, Sudan, Bundibugyo; flaviviruses; influenza; coronaviruses) and bacterial pathogens (Staphylococcus aureus, C. difficile, C. perfringens). Services span in vitro assays (antiviral, bacterial, ELISA, Luminex, flow cytometry, qPCR), animal models (rodent and NHP), GxP compliant testing, pharmacokinetics/biodistribution, concierge program management, and custom assay development. The company operates from Rockville, MD with distribution partners including Thomas Scientific, Abcam, VWR, Fisher Scientific, and international distributors.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-05-13
Description

OEM distribution agreement with IBT Bioservices. Dyadic's C1 protein production platform products are distributed through IBT. Multiple commercial product launches with IBT including recombinant DNase I and transferrin for research applications.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-16
Description

Dyadic Applied BioSolutions announced a commercial distribution partnership with IBT Bioservices, through which Dyadic's recombinant protein products will be marketed via IBT's sales channels. Initial products include recombinant DNase I and transferrin, mainly for research applications. This partnership expands IBT's product portfolio and market reach.

3Thomas Scientific
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for IBT products in the USA

ibtbioservices.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for IBT products in Europe and USA

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for IBT products

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for IBT products

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Distribution partner for IBT products in India and Asia

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Provides biopharmaceutical testing services including viral clearance, biosafety, and biologics characterization. Comparable to IBT's GxP-compliant testing offerings as part of a much larger testing services portfolio.

TypeBroad incumbent
Description

Large public CRO offering preclinical and clinical research services including biologics safety, immunology, and infectious disease models. A broad incumbent with overlapping capabilities but IBT's infectious disease focus is more specialized.

TypeBroad incumbent
Description

Global CRO/CDMO providing preclinical and clinical research services across many therapeutic areas. Overlaps with IBT on biologics testing and assay services at much larger scale and broader scope.

TypeDirect peer
Description

Nonprofit CRO providing preclinical infectious disease research, antiviral/antibacterial screening, and BSL-2/BSL-3 capabilities. Comparable in government-funded infectious disease CRO services and specialized assay work.

TypeDirect peer
Description

Preclinical CRO offering in vivo efficacy models, infectious disease and biodefense research, and GLP-compliant studies. Overlaps directly with IBT's animal model and GxP services for government and biopharma clients.

TypeBroad incumbent
Description

Large clinical trial laboratory services provider offering central lab, bioanalytical, and biomarker testing for clinical trials. Comparable to IBT's clinical trial testing services (Luminex cytokine analysis) at much greater scale.

TypeDirect peer
Description

Specialist infectious disease CRO focused on virology, antiviral, and respiratory challenge studies (flu, RSV, SARS-CoV-2). Directly comparable to IBT in infectious disease preclinical/clinical research services and reagent offerings.

TypeDirect peer
Description

Contract research organization performing infectious disease research, biosafety testing, and government-funded biodefense studies. Comparable to IBT's work for NIAID, NIH, DOD, and BARDA.

TypeDirect peer
Description

Contract research organization with immunology, infectious disease, and assay development capabilities. Provides comparable preclinical research services and government grant-supported programs.

TypeDirect peer
Description

Small infectious disease-focused CRO providing in vitro and in vivo efficacy testing, antiviral/antibacterial assays, and preclinical development services. Comparable niche specialty and customer base to IBT.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IBT Bioservices

Preclinical Contract Research Servicesibtbioservices.com

IBT Bioservices firmographics

Firmographics
Name
IBT Bioservices
Legal name
Integrated Biotherapeutics, Inc.
Website
https://ibtbioservices.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

IBT Bioservices industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Contract research services
  • Preclinical CRO services
  • Infectious disease research
  • Vaccine development services
  • Biological reagent supply

Where IBT Bioservices is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

IBT Bioservices business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. CRO Services Revenue: Preclinical and clinical research services including in vitro assays, animal studies, GxP testing, custom assay development, and concierge services. Revenue generated through project-based contracts and service agreements with biotech, pharma, and government clients.
  2. Reagent Product Sales: Sale of research reagents including recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through e-commerce storefront and distribution partners.
  3. Grant Support Services: Technical consulting and support services for SBIR, NIH, NIAID, BARDA, and DOD grant applications. The team has supported clients in securing over $150M in cumulative grant funding.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goIndividual reagent products priced per unit

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

IBT Bioservices product offering

Product offering

Core offering

IBT Bioservices is a full-service clinical and preclinical Contract Research Organization (CRO) providing research services and biological reagents for vaccine and therapeutic development. The company delivers in vitro assays, animal models, GxP-compliant testing, and concierge program management targeting infectious disease pathogens including filoviruses, flaviviruses, and Staphylococcus aureus. It also manufactures and sells recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through its e-commerce storefront and distribution partners.

Product overview

IBT Bioservices is a Full Service Clinical & Preclinical Contract Research Organization (CRO) offering a comprehensive portfolio of biological reagents and research services for vaccine and therapeutic development. The company's product portfolio includes Recombinant Proteins, Primary Antibodies, Pseudovirus, Virus Like Particles, ELISA Kits, Vaccine Adjuvants, and Cell Lines targeting viral pathogens (filoviruses including Ebola, Marburg, Sudan, Bundibugyo; flaviviruses; influenza; coronaviruses) and bacterial pathogens (Staphylococcus aureus, C. difficile, C. perfringens). Services span in vitro assays (antiviral, bacterial, ELISA, Luminex, flow cytometry, qPCR), animal models (rodent and NHP), GxP compliant testing, pharmacokinetics/biodistribution, concierge program management, and custom assay development. The company operates from Rockville, MD with distribution partners including Thomas Scientific, Abcam, VWR, Fisher Scientific, and international distributors.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • 120+ clients supported for grant applications with $150M+ cumulative funding secured
  • +2 more outcomes

Companies that use IBT Bioservices

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

IBT Bioservices technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IBT Bioservices partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Dyadic InternationalcoreTechnology or Integration · 13 May 2026OEM distribution agreement with IBT Bioservices. Dyadic's C1 protein production platform products are distributed through IBT. Multiple commercial product launches with IBT including recombinant DNase I and transferrin for research applications.
  • Dyadic International / Dyadic Applied BioSolutionscoreChannel Partner/ Reseller/ Distributor · 16 March 2026Dyadic Applied BioSolutions announced a commercial distribution partnership with IBT Bioservices, through which Dyadic's recombinant protein products will be marketed via IBT's sales channels. Initial products include recombinant DNase I and transferrin, mainly for research applications. This partnership expands IBT's product portfolio and market reach.
  • Thomas ScientificminorChannel Partner/ Reseller/ DistributorDistribution partner for IBT products in the USA
  • AbcamminorChannel Partner/ Reseller/ DistributorDistribution partner for IBT products in Europe and USA
  • VWRminorChannel Partner/ Reseller/ DistributorDistribution partner for IBT products
  • Fisher ScientificminorChannel Partner/ Reseller/ DistributorDistribution partner for IBT products
  • Clementia BiotechminorChannel Partner/ Reseller/ DistributorDistribution partner for IBT products in India and Asia

Scale indicators5 records

Recent moves2 records

IBT Bioservices competitors and assessment

Company assessment

Broad incumbents

  • BioReliance (Merck KGaA / Sigma-Aldrich): Provides biopharmaceutical testing services including viral clearance, biosafety, and biologics characterization. Comparable to IBT's GxP-compliant testing offerings as part of a much larger testing services portfolio.
  • Charles River Laboratories: Large public CRO offering preclinical and clinical research services including biologics safety, immunology, and infectious disease models. A broad incumbent with overlapping capabilities but IBT's infectious disease focus is more specialized.
  • WuXi AppTec: Global CRO/CDMO providing preclinical and clinical research services across many therapeutic areas. Overlaps with IBT on biologics testing and assay services at much larger scale and broader scope.
  • IQVIA (Q² Solutions): Large clinical trial laboratory services provider offering central lab, bioanalytical, and biomarker testing for clinical trials. Comparable to IBT's clinical trial testing services (Luminex cytokine analysis) at much greater scale.

Direct peers

  • Southern Research: Nonprofit CRO providing preclinical infectious disease research, antiviral/antibacterial screening, and BSL-2/BSL-3 capabilities. Comparable in government-funded infectious disease CRO services and specialized assay work.
  • Lovelace Biomedical & Environmental Research Institute: Preclinical CRO offering in vivo efficacy models, infectious disease and biodefense research, and GLP-compliant studies. Overlaps directly with IBT's animal model and GxP services for government and biopharma clients.
  • hVIVO: Specialist infectious disease CRO focused on virology, antiviral, and respiratory challenge studies (flu, RSV, SARS-CoV-2). Directly comparable to IBT in infectious disease preclinical/clinical research services and reagent offerings.
  • Battelle Memorial Institute: Contract research organization performing infectious disease research, biosafety testing, and government-funded biodefense studies. Comparable to IBT's work for NIAID, NIH, DOD, and BARDA.
  • SRI International (Biosciences Division): Contract research organization with immunology, infectious disease, and assay development capabilities. Provides comparable preclinical research services and government grant-supported programs.
  • ImQuest BioSciences: Small infectious disease-focused CRO providing in vitro and in vivo efficacy testing, antiviral/antibacterial assays, and preclinical development services. Comparable niche specialty and customer base to IBT.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights7 records

Customer concentration

IBT Bioservices social profiles

Digital presence

IBT Bioservices compliance and trust

Trust signal

Compliance2 records

IBT Bioservices financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IBT Bioservices leadership team

Management profile

Number of profiles

Profiles3 records

IBT Bioservices subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

IBT Bioservices funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IBT Bioservices M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IBT Bioservices

What does IBT Bioservices do?

IBT Bioservices is a full-service clinical and preclinical Contract Research Organization (CRO) providing research services and biological reagents for vaccine and therapeutic development. The company delivers in vitro assays, animal models, GxP-compliant testing, and concierge program management targeting infectious disease pathogens including filoviruses, flaviviruses, and Staphylococcus aureus. It also manufactures and sells recombinant proteins, antibodies, pseudoviruses, ELISA kits, and cell lines through its e-commerce storefront and distribution partners.

Is IBT Bioservices a public or private company?

IBT Bioservices is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IBT Bioservices founded?

IBT Bioservices was founded in 2010. It employs 11 to 50 people.

Where is IBT Bioservices based?

IBT Bioservices is headquartered in Rockville, United States, in the North America region.

How does IBT Bioservices make money?

Three revenue lines are on record. CRO Services Revenue is the primary driver. The others are reagent Product Sales and grant Support Services.

Who are IBT Bioservices's main competitors?

Broad incumbents on record are BioReliance (Merck KGaA / Sigma-Aldrich), Charles River Laboratories, WuXi AppTec and IQVIA (Q² Solutions). Direct peers are Southern Research, Lovelace Biomedical & Environmental Research Institute, hVIVO, Battelle Memorial Institute, SRI International (Biosciences Division) and ImQuest BioSciences.

Does IBT Bioservices have an API?

No public API is recorded for IBT Bioservices.

What industry is IBT Bioservices in?

IBT Bioservices's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 621511 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comDyadic reports Q2 loss amid commercialization efforts By Investing.comDyadic International reported a net loss of $2.1 million for the second quarter ended June 30, 2026, driven by increased costs in grant activities and general expenses despite a reduction in research spending. The company's cash reserves declined to $4.8 million as it advanced commercialization efforts, including shipments to IBT Bioservices and ongoing work with partners like Proliant Health & Biologicals and Fermbox Bio.Stock TitanDyadic Q2 Earnings: Revenue $961K, Net Loss $2.1MDyadic International reported second-quarter 2026 financial results showing total revenue of $961,138 and a net loss of $2.1 million, with cash reserves declining to approximately $4.8 million. The company highlighted progress in commercializing recombinant proteins through partnerships with entities like IBT Bioservices and Proliant Health & Biologicals, while expanding its C1 biomanufacturing platform for global health applications.EIN PresswireDyadic Applied Biosolutions - June Update: C1 Platform Activity and Protein & Enzyme Programs OverviewDyadic Applied Biosolutions highlighted its C1 protein production platform on June 15, 2026, citing speed to produce recombinant antigens in about 15 days. The company launched six animal-free protein products and reported Q1 2026 revenue of $1.11 million, up 182% year over year. Management expects cash runway into 2027.GlobeNewswireDyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial AdoptionDyadic International reported accelerated interest in its C1 protein production platform driven by the ongoing Bundibugyo Ebola virus outbreak and growing commercial adoption across multiple markets. The company highlighted that its C1 platform can progress from gene sequence to purified antigen or monoclonal antibody in approximately 15 days, positioning it as a potential solution for rapid biologics manufacturing during infectious disease threats. Dyadic outlined three collaboration tracks: a partnership with Scripps Research for vaccine and antibody development, research proposals submitted to CEPI's Ebola funding call, and a monoclonal antibody initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub, alongside commercial milestones including product launches with Proliant Health & Biologicals, Fermbox Bio, IBT Bioservices, and Inzymes.Stock TitanDyadic Q1 2026 revenue jumps 182% to $1.11M, loss narrowsDyadic International reported Q1 2026 revenue of $1.11 million, representing a 182% increase from $393,572 in Q1 2025, with the net loss narrowing to $1.95 million from $2.03 million year-over-year. The revenue growth was driven by increases in research and development revenue, grant revenue from CEPI and Gates Foundation activities, and license and milestone revenue. The company also announced multiple commercial milestones including the commercial launch of recombinant human albumin with Proliant Health & Biologicals, expansion of its collaboration with Fermbox Bio including commercializing RNase-free DNase I, and signing OEM distribution and development agreements with IBT Bioservices and BRIG Bio respectively.Investing.comEarnings call transcript: Dyadic Q4 2025 reveals revenue decline, stock up 3.32% By Investing.comDyadic International Inc. reported Q4 2025 financial results with revenue declining 11.7% year-over-year to $3.09 million, primarily due to lower R&D collaboration and license revenues, though grant revenue from Gates Foundation and CEPI partnerships increased significantly. The company reported an operating loss of $7.19 million and net loss of $7.36 million ($0.23 per share), while the stock rose 3.32% to $0.845 following the announcement. Dyadic is transitioning from a development-stage company to a commercial entity with FY2026 revenue guidance set at $7.4 million, driven by new product launches across life sciences, food and nutrition, and bio-industrial segments through partnerships with Proliant, Fermbox Bio, IBT Bioservices, and others.Stock TitanDyadic 2025 revenue falls to $3.09M, cash at $8.6MDyadic International reported 2025 financial results showing total revenue declined to $3.09 million from $3.50 million in 2024, driven by a $638,000 reduction in research and development revenue and a significant drop in license and milestone revenue to $265,000 from $1.89 million. The company's net loss widened to $7.36 million (or $0.23 per share) compared to $5.81 million in 2024, with cash, cash equivalents, and investment-grade securities standing at approximately $8.59 million as of December 31, 2025. Despite the financial decline, Dyadic announced multiple commercial milestones including product launches with Proliant Health & Biologicals and Fermbox Bio, new distribution and development agreements with IBT Bioservices and BRIG Bio, and plans by Inzymes to launch recombinant chymosin in 2026.Stock TitanDyadic Announces 2025 Financial Results and...Dyadic Applied BioSolutions reported its 2025 financial results, showing total revenue of $3.09 million and a net loss of $7.36 million, while highlighting multiple commercial product launches and partnerships. Key developments include the launch of AlbuFree™ DX with Proliant Health & Biologicals, an OEM distribution deal with IBT Bioservices, and expanded collaborations with Fermbox Bio, Inzymes ApS, BRIG BIO, and Opes Diagnostics to commercialize animal-free proteins and enzymes.GlobeNewswireDyadic Announces 2025 Financial Results and Highlights Recent Company ProgressDyadic International reported 2025 financial results with total revenue decreasing to $3.09 million from $3.50 million in 2024, while net loss widened to $7.36 million from $5.81 million, driven by lower license and milestone revenue. The company announced multiple commercial milestones including the commercial launch of AlbuFree DX recombinant human albumin with Proliant Health & Biologicals, expanded collaboration with Fermbox Bio, an OEM distribution agreement with IBT Bioservices, and a development agreement with BRIG Bio for recombinant bovine alpha-lactalbumin.GlobeNewswireDyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT BioservicesDyadic Applied BioSolutions has entered into an OEM distribution agreement with IBT Bioservices to commercialize recombinant protein products including DNase I and recombinant transferrin through IBT's established global sales channels. The partnership represents a strategic milestone for Dyadic as it transitions from R&D-driven revenue toward commercial product sales, leveraging IBT's distribution infrastructure to expand market access and support ongoing product-based revenues. The collaboration also provides flexibility for potential future expansion including partner-led manufacturing through licensing of production strains.